GlassScriptPhysician profile
Maya Hosein
NPI 1336307586
$3,853.23
in general payments reported to CMS, 2019-2025
33 companies · $895 in 2025
The $895 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $421 · 2020: $269 · 2021: $289 · 2022: $775 · 2023: $413 · 2024: $792 · 2025: $895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,990 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,989.56 |
| Education | $109.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $949.10 | 2019-2025 | Lifevest |
| Glaxosmithkline, LLC. | $663.69 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Genzyme Corporation | $310.97 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $263.95 | 2019-2025 | Opsumit, Uptravi |
| Baxter Healthcare | $214.95 | 2022-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Abbott Laboratories | $191.02 | 2022 | |
| Insmed, INC. | $182.57 | 2021-2025 | Brinsupri, Arikayce |
| Alexion Pharmaceuticals, INC. | $165.24 | 2022-2023 | Ultomiris, Soliris |
| Grifols USA, LLC | $163.32 | 2022-2025 | Prolastin-C Liquid |
| Ani Pharmaceuticals, INC. | $108.83 | 2024-2025 | Purified Cortrophin Gel |
| Astrazeneca Pharmaceuticals LP | $54.53 | 2021-2025 | Airsupra, Tezspire |
| Vapotherm INC | $49.77 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $48.95 | 2024-2025 | Dupixent |
| Mylan Specialty L.P. | $45.56 | 2019-2022 | |
| Ceribell, INC. | $44.86 | 2025 | Pocket Eeg Device |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $44.85 | 2019-2025 | Winrevair |
| Chiesi USA, INC. | $36.31 | 2025 | Cleviprex |
| Abbvie INC. | $33.93 | 2023 | |
| United Therapeutics Corporation | $30.11 | 2019 | |
| Novo Nordisk INC | $27.54 | 2021 | |
| Viatris Specialty LLC | $26.14 | 2025 | Yupelri |
| Mallinckrodt Enterprises LLC | $26.02 | 2019 | |
| Pfizer INC. | $24.28 | 2025 | |
| Boston Scientific Corporation | $21.37 | 2022 | |
| Pulmonx Corporation | $18.41 | 2024 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Sunovion Pharmaceuticals INC. | $16.66 | 2019 | |
| Amarin Pharma, INC. | $15.13 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.90 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.12 | 2024 | Glassia |
| E.R. Squibb & Sons, L.L.C. | $12.88 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.61 | 2019 | |
| Medtronic Vascular, INC. | $11.22 | 2019 | |
| Inogen, INC. | $10.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maya Hosein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.